Funder
National Cancer Institute
Reference40 articles.
1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;The New England journal of medicine,2015
2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;The New England journal of medicine,2015
3. Pembrolizumab versus chemotherapy for pd-l1-positive non-small-cell lung cancer;Reck;The New England journal of medicine,2016
4. Pembrolizumab versus chemotherapy for previously untreated, pd-l1-expressing, locally advanced or metastatic non-small-cell lung cancer (keynote-042): A randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019
5. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;The New England journal of medicine,2018